Refers to a Pharmaceutical composition comprising at least 150 mg and up to 700 mg ceritinib and over 40% to 70% by weight of ceritinib based on the total weight of the pharmaceutical composition, wherein the composition comprises Granules consisting substantially of a ceritinib and AGL Utinante where Granules are obtained by Wet granulation The Binder is Starch.Hypromellose, povidone, among others, Said composition also includes other excipients. It also relates to a Pharmaceutical Form and a production process. The composition that Inhibits the Enzyme anaplastic Lymphoma Kinase (alk) is useful in the treatment of proliferative disease such as non small cell lung cancerSe refiere a una composicion farmaceutica que comprende al menos 150 mg y hasta 700 mg de Ceritinib y mas de 40% y hasta 70% por peso de Ceritinib con base en el peso total de la composicion farmaceutica, en donde la composicion comprende granulos que consisten sustancialmente de Ceritinib y un aglutinante donde los granulos son obtenibles mediante granulacion humeda el aglutinante es almidon, hipromelosa, povidona, entre otros, dicha composicion comprende ademas otros excipientes. Tambien se refiere a una forma farmaceutica y un proceso de obtencion. Dicha composicion inhibe la enzima quinasa del linfoma anaplasico (ALK) siendo util en el tratamiento de enfermedad proliferativa tal como cancer de pulmon de celulas no pequenas
